Roche announced its anti-ST2 monoclonal antibody astegolimab failed to reduce flare-ups in a pivotal Phase 3 study for chronic obstructive pulmonary disease (COPD). The setback significantly dims hopes for regulatory approval this year, posing a challenge to Roche’s respiratory drug portfolio and underscoring the difficulty of developing efficacious COPD biologics.